Health
Vaxcyte Advances in Pneumococcal Vaccine Race
Vaxcyte announced success in a Phase 3 clinical trial for its pneumococcal vaccine, competing with Pfizer and Merck. The biotech aims to capture a lucrative market share.
Coverage timeline — 1 article
STAT News
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
2026-10-05 12:19 UTC